Patents by Inventor Max S. Wicha
Max S. Wicha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11426729Abstract: The present disclosure relates to systems and methods for whole cell analysis. In particular, the present disclosure relates to single cell genomic analysis (e.g., gene expression analysis.Type: GrantFiled: January 19, 2018Date of Patent: August 30, 2022Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Euisik Yoon, Yu-Heng Cheng, Yu-Chih Chen, Riley Brien, Max S. Wicha
-
Patent number: 10677708Abstract: A microfluidic device for detecting rare cells in a fluid sample comprises the rare cell and other cells. The microfluidic device comprises an inlet for receiving the fluid sample, a labyrinth channel structure in fluid communication with the inlet, and an outlet in fluid communication with the labyrinth channel structure for collecting the rare cells separated from the other cells in the fluid sample. The labyrinth channel structure comprises at least one channel through which the fluid sample flows. The at least one channel has a plurality of segments and a plurality of corners with each corner defined between adjacent segments. The presence of the plurality of corners induces separation of the rare cells from the other cells in the fluid sample as the rare cells move to a first equilibrium position within the at least one channel when a ratio of inertial lift forces (FZ) and Dean flow (FD) of the fluid sample is from 2 to 10.Type: GrantFiled: August 10, 2018Date of Patent: June 9, 2020Assignee: The Regents of the University of MichiganInventors: Sunitha Nagrath, Hyeun Joong Yoon, Eric Lin, Max S. Wicha, Lianette Rivera Baez, Diane M. Simeone
-
Patent number: 10557850Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: GrantFiled: December 10, 2014Date of Patent: February 11, 2020Assignee: THE REGENTS OF UNIVERSITY OF MICHIGANInventors: Max S. Wicha, Christophe Ginestier
-
Publication number: 20190344270Abstract: The present disclosure relates to systems and methods for whole cell analysis. In particular, the present disclosure relates to single cell genomic analysis (e.g., gene expression analysis.Type: ApplicationFiled: January 19, 2018Publication date: November 14, 2019Inventors: Euisik Yoon, Yu-Heng Cheng, Yu-Chih Chen, Riley Brien, Max S. Wicha
-
Patent number: 10227567Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: GrantFiled: September 7, 2016Date of Patent: March 12, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20190017919Abstract: A microfluidic device for detecting rare cells in a fluid sample comprises the rare cell and other cells. The microfluidic device comprises an inlet for receiving the fluid sample, a labyrinth channel structure in fluid communication with the inlet, and an outlet in fluid communication with the labyrinth channel structure for collecting the rare cells separated from the other cells in the fluid sample. The labyrinth channel structure comprises at least one channel through which the fluid sample flows. The at least one channel has a plurality of segments and a plurality of corners with each corner defined between adjacent segments. The presence of the plurality of corners induces separation of the rare cells from the other cells in the fluid sample as the rare cells move to a first equilibrium position within the at least one channel when a ratio of inertial lift forces (FZ) and Dean flow (FD) of the fluid sample is from 2 to 10.Type: ApplicationFiled: August 10, 2018Publication date: January 17, 2019Applicant: The Regents of the University of MichiganInventors: Sunitha Nagrath, Hyeun Joong Yoon, Eric Lin, Max S. Wicha, Lianette Rivera Baez, Diane M. Simeone
-
Patent number: 10073024Abstract: A microfluidic device for detecting rare cells in a fluid sample comprises the rare cell and other cells. The microfluidic device comprises an inlet for receiving the fluid sample, a labyrinth channel structure in fluid communication with the inlet, and an outlet in fluid communication with the labyrinth channel structure for collecting the rare cells separated from the other cells in the fluid sample. The labyrinth channel structure comprises at least one channel through which the fluid sample flows. The at least one channel has a plurality of segments and a plurality of corners with each corner defined between adjacent segments. The presence of the plurality of corners induces separation of the rare cells from the other cells in the fluid sample as the rare cells move to a first equilibrium position within the at least one channel when a ratio of inertial lift forces (FZ) and Dean flow (FD) of the fluid sample is from 2 to 10.Type: GrantFiled: October 29, 2013Date of Patent: September 11, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Sunitha Nagrath, Hyeun Joong Yoon, Eric Lin, Max S. Wicha, Lianette Rivera Baez, Diane M. Simeone
-
Patent number: 9801922Abstract: The invention provides compositions and methods to treat cancer with an agent that increases reactive oxygen species (ROS) levels in cancer cell mitochondria (“an XTPP agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.Type: GrantFiled: August 2, 2012Date of Patent: October 31, 2017Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION, REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Douglas R. Spitz, Michael K. Schultz, Kyle Kloepping, Yueming Zhu, Nukhet Aykin-Burns, Max S. Wicha
-
Publication number: 20170175083Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: ApplicationFiled: September 7, 2016Publication date: June 22, 2017Inventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Patent number: 9606124Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: GrantFiled: December 10, 2014Date of Patent: March 28, 2017Assignee: The Regents of the University of MichiganInventors: Max S. Wicha, Christophe Ginestier
-
Patent number: 9492538Abstract: A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.Type: GrantFiled: June 10, 2005Date of Patent: November 15, 2016Assignee: The Regents of the University of MichiganInventors: Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj
-
Patent number: 9352039Abstract: Compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states are disclosed. In some methods, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain methods, the different states of cancer stem cells are distinguished based on markers CD44+CD24?, EpCam?CD49P+ (for EMT cancers stem cells), ALDH+ and EPCam+CD49r? (for MET cancers stem cells), and CD44+CD24?ALDH+ (for EMT-MET cancer stem cells). In particular methods, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).Type: GrantFiled: February 8, 2013Date of Patent: May 31, 2016Inventors: Suling Liu, Max S. Wicha
-
Patent number: 9327023Abstract: The present invention relates to compositions, methods, and kits for treating cancers with HER2 targeting agents and preventing resistance thereto. In particular embodiments, non-HER2-amplified cancers are treated with HER2 targeting agents, wherein the cancer stem cells in the cancer express HER2 and/or HER2 indicator marker. The present invention also relates to compositions, methods, and kits for detecting expression of HER2 and/or a HER2 indicator marker in non-HER2-amplified cancer samples from a subject, and identifying the subject as responsive to treatment with a HER2 targeting agent and/or treating the subject with a HER2 targeting agent.Type: GrantFiled: October 25, 2012Date of Patent: May 3, 2016Assignee: The Regents of the University of MichiganInventors: Max S. Wicha, Hasan Korkaya
-
Publication number: 20150293010Abstract: A microfluidic device for detecting rare cells in a fluid sample comprises the rare cell and other cells. The microfluidic device comprises an inlet for receiving the fluid sample, a labyrinth channel structure in fluid communication with the inlet, and an outlet in fluid communication with the labyrinth channel structure for collecting the rare cells separated from the other cells in the fluid sample. The labyrinth channel structure comprises at least one channel through which the fluid sample flows. The at least one channel has a plurality of segments and a plurality of corners with each corner defined between adjacent segments. The presence of the plurality of corners induces separation of the rare cells from the other cells in the fluid sample as the rare cells move to a first equilibrium position within the at least one channel when a ratio of inertial lift forces (FZ) and Dean flow (FD) of the fluid sample is from 2 to 10.Type: ApplicationFiled: October 29, 2013Publication date: October 15, 2015Inventors: Sunitha Nagrath, Hyeun Joong Yoon, Eric Lin, Max S. Wicha, Lianette Rivera Baez, Diane M. Simeone
-
Patent number: 9089556Abstract: The invention provides methods for treating cancer via administering to a patient having a solid tumor a therapeutically effective amount of an antibody against Delta-like ligand 4(Dll4) or other Notch pathway components. The solid tumor may comprise solid tumor stem cells.Type: GrantFiled: March 12, 2013Date of Patent: July 28, 2015Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Michael F. Clarke, Max S. Wicha, Muhammad Al-Hajj
-
Publication number: 20150160227Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: ApplicationFiled: December 10, 2014Publication date: June 11, 2015Inventors: Max S. Wicha, Christophe Ginestier
-
Publication number: 20150125469Abstract: Compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states are disclosed. In some methods, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain methods, the different states of cancer stem cells are distinguished based on markers CD44+CD24?, EpCam?CD49P+(for EMT cancers stem cells), ALDH+ and EPCam+CD49r? (for MET cancers stem cells), and CD44+CD24?ALDH+ (for EMT-MET cancer stem cells). In particular methods, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).Type: ApplicationFiled: February 8, 2013Publication date: May 7, 2015Inventors: Suling Liu, Max S. Wicha
-
Publication number: 20150094362Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: ApplicationFiled: December 10, 2014Publication date: April 2, 2015Inventors: Max S. Wicha, Christophe Ginestier
-
Patent number: 8940301Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).Type: GrantFiled: November 11, 2009Date of Patent: January 27, 2015Assignee: The Regents of The University of MichiganInventors: Max S. Wicha, Christophe Ginestier
-
Publication number: 20140228290Abstract: The invention provides compositions and methods to treat cancer with an agent that increases reactive oxygen species (ROS) levels in cancer cell mitochondria (“an XTPP agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.Type: ApplicationFiled: August 2, 2012Publication date: August 14, 2014Applicants: REGENTS OF THE UNIVERSITY OF MICHIGAN, UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Douglas R. Spitz, Michael K. Schultz, Kyle Kloepping, Yueming Zhu, Nukhet Aykin-Burns, Max S. Wicha